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57 ABSTRACT 
The invention is directed to compositions which alter the 
health of invertebrate organisms by affecting eicosanoid 
mediated immune responses, and methods of using the 
compositions. The invention provides pharmaceutical com 
positions and biopesticide compositions. The pharmaceuti 
cal composition is composed of an effective amount of at 
least one biologically active agent which enhances or inhib 
its eicosanoid-mediated immune responses in invertebrate 
Species and a physiological compatible carrier. The biope 
Sticide composition is composed of a biopesticidal amount 
of an inhibitor of eicosanoid-mediated immune responses in 
invertebrates and a physiologically acceptable carrier. The 
pharmaceutical compositions are useful to treat invertebrate 
Species to enhance or inhibit immune responses. The bio 
pesticide composition is useful to control the growth of or 
eradicate invertebrate pests. Methods are provided for deter 
mining which and what amounts of the biologically active 
agents are useful in the composition. 
12 Claims, No Drawings 
6,099,834 
Page 2 
OTHER PUBLICATIONS 
R. Newton, “Steric Control In Prostaglandin Synthesis 
Involving Bicyclic and Tricyclic Intermediates”, Tetrahe 
dron, 36:2163–2196 (1980). 
R. Newton et al., “Strategies Employed in the Synthesis of 
Protocyclins and Thromboxanes', Synthesis at pp. 449-478 
(1984). 
N. Porter et al., “Prostaglandin G', J. Am. Chem. Soc., 
102:1183–1184 (1980). 
B. Samuelsson, “Leukotrienes, Mediators of Immediate 
Hypersensitivity Reactions and Inflammation”, Science, 
220:568-575 (1983). 
Sih et al., “Asymmetric Total Synthesis of (-)-Prostaglandin 
E. and (-)-Prostaglandin E, J. Am. Chem. Soc., 
97:865-874 (1975). 
D. White, “Prostaglandin Synthesis: Regio-Specific Gen 
eration of a Latent Mixed Acyloin Under Neutral Condi 
tions”, Tetrahedron Lett., 21:1753–1756 (1976). 
D. Anthony, “Status of Research on Biological Agents for 
the Control of Mosquitos”, in Fundamental and Applied 
Aspects of Invertebrate Pathogens, Proceedings of the 4th 
International Colloquium of Invertebrate Pathology, at pp. 
176–193 (1986). 
N. Becker et al., “Application of Irradiated Bacterial Insec 
ticides in an Integrated Mosquito Control Program in West 
Germany', in Fundamental and Applied Aspects of Inver 
tebrate Pathogens, Proceedings of the Fourth International 
Colloquium of Invertebrate Pathology, at p. 559 (1986). 
H. Boman et al., “Cell-Free Immunity in Insects”, Ann. Rev. 
Microbiol., 41:103–126 (1987). 
H. Burges et al., “Current Status of the Use of Bacteria as 
Biocontrol Agents', in Fundamental and Applied Aspects of 
Invertebrate Pathogens, Proc. of the 4th International Col 
loquium of Invertebrate Pathology, pp. 514-517 (1986). 
K. Cutler et al., “Compound Discovered That Destroys 
Insect Immune Systems”, in AgBiotechnology News, p. 3 
(May/Jun. 1991). 
R. Faust, Nature of Pathogenic Process of Bacillus thuring 
iensis, in Fundamental and Applied Aspects of Invertebrate 
Pathogens, Proc. of the 4th International Colloquium of 
Invertebrate Pathology, pp. 91-129 (1986). 
J. Jarosz et al., “Selective Inhibition of Cecropin-like Activ 
ity of Insect Immune Blood by Protease from American 
Foulbrood Scales”, J. Invert. Path., 56.143-149 (1990). 
V. Miller, “Entomologist Finds Way to Halt Insect Immune 
Response”, CO-WY NE-IA-SD (May 13, 1991). 
V. Miller, “UNL Scientists Direct Attack on Killer Tomato 
Worms”, Exploring Life's Frontiers, p. 7 (Apr. 1991). 
V. Miller, “Team Finds Way to Block Insects' Immune 
Response", Research Nebraska, pp. 8-9 (Mar. 1991). 
C. Pant, “Ecology and Control of Vectors: Use of Biological 
Agents as a Component of Integrated Vector Control Pro 
grammes, in Fundamental and Applied Aspects of Inver 
tebrate Pathogens, Proceedings of the 4th International 
Colloquium of Invertebrate Pathology, at pp. 501-509 
(1986). 
N. Ratcliffe, “Invertebrate Immunity-A Primer for the 
Non-Specialist”, Immun. Lett., 10:253–270 (1985). 
B. Ruggeri, “The Identification of Several Prostaglandin 
Moieties in CrassOstrea Virginica and Mytilus Edulis by 
Radioimmunoassay and High Performance Liquid Chroma 
tography”, ProStaglandins Leukotrienes and Medicine, 
20:69–77 (1985). 
A. Sparks, “Penaeid Bacterial Septicemia. Syn. Penaeid 
Vibriosis”, in Synopsis of Invertebrate Pathology. Exclusive 
of Insects, Elsevier Science Publishers B.V., at pp. 197-199 
(1985). 
A. Undeen, “Biological Control of the Psychodidae, Cer 
atopogonidae, and Simulildae (Diptera), Including New 
Data on the Effect of Bacillus thuringiensis Var. israelensis 
on Simuliidae”, in Fundamental and Applied Aspects of 
Invertebrate Pathogens, Proceedings of the 4th International 
Colloquium of Invertebrate Pathology, at pp. 143-153 
(1986). 
B. Salafsky et al., “Schistosoma Mansonia: A Comparison of 
Secreted Versus Non-Secreted Euicosanoids in Developing 
Schistosomulae in Adults”, Experimental Parasitology, 
64:361 (1987). 
Fletcher et al., “Structure of the Mitogen-inducible TIS10 
Gene and Demonstration That the TIS 10-encoded protein is 
a Functional Prostaglandin G/H Synthase'.J. Biol. Chem., 
267:4338 (1992). 
Pawlowski et al., “Cloning and Sequencing of the cDNA for 
Rat Liver 3-alpha-Hydroxysteroid/Dihydrodiol Dehydro 
genase”, J. Biol. Chem., 266:8820 (1991). 
Funk et al., “Human Platelet/Erythroleukemia Cell Prostag 
landin G/HSynthase: cDNA Cloning, Expression, and Gene 
Chromosomal Assignment”, FASEB Journal, 5:2304(1991). 
Cheng et al., “Molecular Cloning and Expression of Rat 
Liver 3-alpha-Hydroxysteroid Dehydrogenase”, Mol. 
Endocrinology, 5:823 (1991). 
Watanabe et al., “Expression of Bovine Lung Prostaglandin 
F Synthase in Escherichia coli'', Biochem. and BiophyS. 
Res. Comm., 181:272 (1991). 
Seilhamer et al., “Pancreatic Phospholipase A: Isolation of 
the Human Gene and cDNAS from Porcine Pancreas and 
Human Lung", DNA, 5:519 (1986). 
Ha et al., “Identification of Upstream Regulatory Elements 
Involved in the Developmental Expression of the Arabidop 
sis thaliana cabl Gene", PNAS, 85:8017 (1988). 
Lam et al., “Site-specific Mutations Alter in vitro Factor 
Binding and Change Promoter Expression Pattern in Trans 
genic Plants", PNAS, 86:7890 (1989). 
Channon et al., “A Calcium-dependent Mechanism for 
ASSociating a Soluble Arachiodonoyl-hydrolyzing Phos 
pholipase A with Membrane in the Macrophage Cell Line 
RAW 264.7", J. Biol. Chem..., 265:5409 (1990). 
Ragab-Thomas et al., “Pathways of Arachiodonic Acid 
Liberation in Thrombin and Calcium Ionophore 
A23187-Stimulated Human Endothelial Cells: Respective 
Roles of Phospholipids and Triacylglycerol and Evidence 
for Diacy glycerol Generation from Phosphatidylcholine”, 
BBA, 917:388 (1987). 
Ragab et al., “Phospholipase A Activity in Reproductive 
Tissues of the Firebrat Thermobia Domestica (Insecta: 
Thysanura)”, Insect Biochem. Molec. Biol., 22:379 (1992). 
Ratcliffe, “Invertebrate Immunity-A Primer for the 
Non-Specialist', Immunology Letters, 10 at pp. 257-261 
(1985). 
Kirk-Othmer, Encyclopedia of Chemical Technology, Third 
Edition (Supplement Volume), John Wiley & Sons, publish 
ers, at pp. 714-719. 
6,099,834 
1 
METHOD FOR MODULATING ECOSANOID 
MEDIATED IMMUNE RESPONSES IN 
ARTHROPODS 
This is a file-wrapper continuation of application Ser. No. 
08/371,471 filed on Dec. 19, 1994, now abandoned which is 
a file wrapper continuation of application Ser. No. 08/133, 
555, filed Oct. 7, 1993, abandoned, which is a continuation 
of application Ser. No. 07/825,671, filed Jan. 30, 1992, 
abandoned. 
BACKGROUND OF THE INVENTION 
Invertebrates comprise 95% of all known species in the 
animal kingdom and include a vast diversity of animals from 
unicellular protozoans to the more complex echinoderms 
and protocordates. Many Species of invertebrates are pests, 
especially the 750,000 known species of insects which 
compete with man for agricultural, forestal and animal 
products. Other invertebrate Species act as Vectors of dis 
easeS Such as malaria and trypanoSomiasis which affect 
more than one billion people. In contrast, Some invertebrate 
Species Serve as food Sources, Such as mollusks and 
crustaceans, and are of commercial importance and, in Some 
cases, commercially farmed. Thus, management of inverte 
brate Species is important because of the impact of agricul 
ture pests on the availability of food and other resources, the 
impact of Vector born disease on human health, and the 
impact of disastrous outbreaks of disease in invertebrates of 
commercial importance. 
One management Strategy for control of invertebrate 
vectors of human or animal disease or agricultural pests 
involves the use of chemical pesticides. However, many pest 
Species have never been Successfully controlled with chemi 
cal pesticides. Moreover, Some of the most effective chemi 
cal pesticides, like DDT, have been banned from use because 
of environmental and health concerns. Those pest Species 
which have been successfully controlled or eradicated with 
chemical pesticides can become resistant to the chemical 
pesticides, necessitating the development of new chemical 
formulations. Although, chemical pesticides are still widely 
used, the problems of environmental contamination, risk to 
human health, and resistance represent Serious drawbacks to 
relying Solely on chemicals in the management of inverte 
brate pests. 
The current management Strategy of invertebrate pests 
involves integration of Several different approaches includ 
ing the use of biological control agents with or without the 
use of chemical pesticides. The biological control agents 
currently in use are either pathogens, parasites or predators 
(mostly larvivorous fish). A biological control agent used 
successfully is Bacillus thurigiensis which provides a toxin 
used to control growth of mosquitos, black flies, Spruce bud 
Worm, gypsy moth and lepidopterous pests. However, use of 
Bacillus thurigiensis and other infectious agents as pesti 
cides represent less than 1% of the pesticide market. Bio 
logical pesticides have Several drawbacks including higher 
cost, limited host range, low virulence, Short shelf life, and 
difficulty in transportation. A better understanding of inver 
tebrate immune defense mechanisms may contribute to 
optimal utilization of available biological pesticides and to 
the development of new biological control agents. 
Management of commercially valuable invertebrate Spe 
cies is becoming more important as unfavorable conditions 
in aquacultures, commercial farms and the natural environ 
ment have led to an increase in fatal disease outbreaks. 
Unfavorable conditions include pollution of water and soils, 
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crowded conditions that promote fighting and cannibalism 
and immobilization or capture of organisms which cause 
wounds. Commercial Species of importance held in crowded 
conditions, like annelids, oysters, lobsters, penaeid shrimp, 
and soft-shelled crabs, can be decimated by infection with 
Viruses, bacteria or fungi. Attempts to prevent these infec 
tions have not been described and an investigation of the 
immune response of these invertebrate Species is essential to 
developing a strategy to prevent loSS of these species both in 
nature and in the commercial farms. 
Like Vertebrate Species, the immune System of inverte 
brates plays a central role in the resistance of the organisms 
to disease, however, little is known about invertebrate 
immune systems. It is known that invertebrates have both 
cellular and humoral components that can act in a coordi 
nated way to provide protection from invading pathogens. 
Cellular responses mediated by hemocytes include 
phagocytosis, encapsulation, and various cytotoxic reactions 
Such as release of lysozyme and activation of the prophenol 
oxidase System. These cellular responses are complimented 
by anti-bacterial action of lysozyme and anti-bacterial pep 
tides known as the cecropins, attacins, diptericins and insect 
defensins. However, little is known about the early steps of 
the immune response as, for example, the transduction of 
foreign body invasion signals and Subsequent initiation of 
early physiological defense responses. These early Steps can 
be important in the eventual outcome of the infection, for 
example, an early immune response may prevent significant 
multiplication of a bacterial pathogen thereby preventing or 
delaying death of the host invertebrate. 
Therefore it is an object of the present invention to 
identify Steps in the invertebrate immune response, includ 
ing early steps. It is also an object of the invention to develop 
compositions which can inhibit or Stimulate the immune 
response in invertebrates. It is a further object of the 
invention to provide biopesticide compositions and methods 
of using these biopesticides to control growth of Vectors of 
human disease and agricultural invertebrate pests. It is also 
an object of the invention to provide therapeutic composi 
tions and methods of using therapeutic compositions to 
prevent fatal infections of invertebrate Species of commer 
cial value. 
SUMMARY OF THE INVENTION 
These and other goals are achieved by the present inven 
tion which is directed to a pharmaceutical composition 
which alters the health of invertebrate organisms by affect 
ing the eicosanoid-mediated immune responses, and a 
method of using the composition. The pharmaceutical com 
position can be used in the treatment of invertebrates to 
enhance or to inhibit immunological responses. The inven 
tion also provides for a biopesticide composition and 
method of using the biopesticide to control or eradicate 
invertebrate pests. Methods are provided for determining 
which biologically active agents and what amounts are 
useful in the composition. 
The pharmaceutical composition is an admixture of an 
effective immunoregulatory amount of at least one biologi 
cally active agent which modulates invertebrate eicosanoid 
mediated immune responses and a physiological acceptable 
or biocompatible carrier. The biologically active agent can 
act to inhibit or enhance eicosanoid-mediated immune 
responses. An effective immunoregulatory amount is that 
amount of the biologically active agent which results in a 
change in the immune response. Agents which inhibit inver 
tebrate eicosanoid biological activity can provide for an 
6,099,834 
3 
increase in Susceptibility to disease and for an increase in 
mortality of the invertebrate species. Agents which enhance 
or Stimulate invertebrate eicosanoid biological activity can 
provide for a decrease in Susceptibility to disease and a 
decrease in mortality of the invertebrate Species. The bio 
logically active agent can also be one which acts primarily 
to modulate eicosanoid immune response without modifying 
or altering other invertebrate biological functions like repro 
ductive function or water transport functions. 
The invention provides for a method to determine whether 
and what amounts of the biologically active agent is effec 
tive to modulate eicosanoid-mediated immune responses in 
invertebrates useful in the pharmaceutical composition of 
the invention. An amount of the biologically active agent 
which modulates eicosanoid biosynthesis in a carrier is 
administered to an invertebrate Species to yield a test popu 
lation. The control population of the invertebrate Species 
receives the carrier alone. Both the control and test popu 
lations are inoculated with an infectious agent and incubated 
for a sufficient time to allow for growth of the infectious 
agent. After incubation, tissue Samples are withdrawn from 
test and control groups and plated on effective growth 
medium to provide for growth of infectious agent. The 
amount of the infectious agent recovered from the test 
population is compared to that of the control population. An 
increase or decrease in the amount of the infectious agent 
recovered from tissues from the test population in compari 
Son with the amount recovered from the control tissue 
indicates whether and what amounts of biologically active 
agent administered to the invertebrate results in a change in 
the immune response. 
Agents which can inhibit invertebrate eicosanoid 
mediated immune responses can include antagonists of 
prostaglandins, leukotrienes and arachidonic acid, inhibitors 
of the enzymes of eicosanoid biosynthetic pathways, altered 
intermediates and/or altered enzymes of eicosanoid biosyn 
thetic pathways, and inhibitors of Signal molecules which 
turn on eicosanoid biosynthesis. Preferably, the biologically 
active agent is an inhibitor of the enzymes of the eicosanoid 
biosynthetic pathway, and more preferably the inhibitor is a 
peptide which blocks the active site of an enzyme in the 
eicosanoid biosynthetic pathway. 
Agents which can enhance or Stimulate invertebrate 
eicosanoid-mediated immune responses include 
prostaglandins, leukotrienes, arachidonic acid and analogs 
thereof, agents which Stimulate the enzymes of eicosanoid 
biosynthetic pathways, altered enzymes of the eicosanoid 
biosynthetic pathway, inhibitors of inactivating enzymes 
like dehydrogenases and reductases, and agents which 
Stimulate Signal molecules which turn on eicosanoid bio 
Synthesis. Preferably, the biologically active agent is an 
analog of a prostaglandin, leukotriene, or arachidonic acid 
and more preferably, an analog which is orally active, has 
prolonged duration of biological activity and increased 
potency when compared to naturally occurring eicosanoids. 
The biologically active agent can also be a genetically 
engineered organism which, expresses, Secretes and delivers 
an agent which alters eicosanoid-mediated immune 
responses. Suitable organisms can be genetically-engineered 
yeast, bacteria, Viruses, plants or fungi. The organism is 
preferably a microorganism which can infect and grow in the 
particular invertebrate Species and, more preferably, a patho 
genic microorganism. Genes can be cloned and introduced 
into the organism by standard recombinant DNA methods 
and include genes encoding the enzymes of the eicosanoid 
biosynthetic pathway, genes encoding altered enzymes of 
the eicosanoid biosynthetic pathway, genes encoding altered 
15 
25 
35 
40 
45 
50 
55 
60 
65 
4 
Signal transduction molecules, and genes encoding peptides 
which block the active site of the enzymes of the eicosanoid 
biosynthetic pathway. In a preferred version, a pathogenic 
bacteria like Serratia marceScens, is transformed with a 
plasmid containing a gene encoding a peptide which blockS 
or inhibits the active site of an enzyme of the eicosanoid 
biosynthetic pathway So that the pathogen expresses, 
Secretes and delivers the peptide inhibitor to the target 
invertebrate Species. 
The biologically active agent is combined with a Suitable 
carrier which functions to assist delivery of the agent to the 
appropriate Site. The choice of carrier depends upon the 
habitat of the invertebrate, type of food consumed by the 
invertebrate, and the physical characteristics of the biologi 
cally active agent. The biologically active agent is Substan 
tially soluble or dispersible in the carrier and the carrier is 
physiologically acceptable or compatible with invertebrates, 
plants, fish and other vertebrate organisms. The carrier can 
function to help the biologically active agent adhere to plant 
leaves and other food Sources consumed by the target 
invertebrate Species. The carrier can also function to allow 
the biologically active agent to adhere and/or penetrate to 
the external skeletons, shells or cuticle of invertebrate Spe 
cies. The carrier can also be a food Source for the inverte 
brate Species. The carrier can be formulated into a liquid or 
powdered mixture for Spray delivery, or as granules or 
liposomes. The carrier of the composition may further be 
comprised of a Surface-active agent. The Surface-active 
agent readily disperses in the carrier and increases the 
adherence and/or penetration of the carrier and biologically 
active agent to a target site. 
The invention also provides for a biopesticide composi 
tion comprised of an effective pesticidal amount of at least 
one biologically active agent which inhibits eicosanoid 
mediated immune responses of an invertebrate organism and 
a physiological acceptable carrier. An effective pesticidal 
amount is that amount of the biologically active agent which 
inhibits eicosanoid-mediated immune responses Sufficiently 
to cause an increase in the mortality of the invertebrate 
organism. The effective pesticidal amount for a particular 
invertebrate Species can be determined by a method pro 
vided for in the invention. 
The biopesticide composition can further comprise a 
chemical or biological pesticide in one or a plurality of 
applications as dictated by the characteristics of the particu 
lar invertebrate species to be controlled or eradicated. The 
chemical or biological pesticides currently in use rarely 
result in total control or eradication of the invertebrate 
Species. Resistant or Surviving invertebrate larvae or adults 
Simultaneously or Subsequently exposed to a biological 
agent which inhibits eicosanoid biological activity can 
exhibit an inhibition of immune responses, an increase in 
Susceptibility to infectious disease, and an increase in mor 
tality. The biologically active agent can act together with 
other biological control agents, like Bacillus thurigiensis. 
The invention also provides a method for altering the 
health of invertebrate animals by administering an effective 
immunoregulatory amount of a pharmaceutical composition 
containing a biologically active agent which modulates 
eicosanoid-mediated immune responses. An effective immu 
noregulatory amount is that amount of the biologically 
active agent which results in a change in the immune 
response. The pharmaceutical composition is administered 
by combining it with a food or water Source and feeding it 
to the invertebrate Species, by injecting, or preferably by 
Spraying the composition onto the invertebrate and/or its 
food or water Source. The composition can be formulated 
6,099,834 
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into a liquid, powder, granules, or Sustained release and/or 
macro/micro capsules. The composition can further com 
prise antioxidants, UV protectants, and Sustained release 
polymers. 
A treatment method is provided wherein the biologically 
active agent is administered to an invertebrate Species in an 
amount to decrease immune response capabilities making 
the invertebrate more Susceptible to infectious disease and 
less likely to Survive. A similar treatment method provides 
for administration of the biologically active agent in an 
effective amount to enhance immune response capabilities, 
making the organism leSS Susceptible to infectious disease 
and more likely to Survive an infectious disease challenge. 
The invention also provides a method of controlling the 
growth of invertebrate pests by administering an effective 
pesticidal amount of a biopesticide composition to an inver 
tebrate species until growth is effectively inhibited. The 
biopesticide composition is composed of at least one bio 
logically active agent which inhibits eicosanoid-mediated 
immune responses and a physiological carrier. The compo 
Sition is administered by combining it with a food or water 
Source and feeding it to the invertebrate Species, injecting, 
and preferably by Spraying the biopesticide composition 
onto the invertebrate and/or its food and water Source. An 
effective biopesticidal amount is that amount of the biologi 
cally active agent which inhibits the eicosanoid-mediated 
immune response Sufficiently to cause an increase in the 
mortality of the invertebrate species. The composition is 
administered in a Single or a plurality of applications until 
the growth of the invertebrate species is effectively inhib 
ited. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The pharmaceutical composition useful to alter the health 
of invertebrate organisms is formed by mixing an effective 
immunoregulatory amount of at least one biologically active 
agent which modulates eicosanoid-mediated immune 
responses and a physiologically acceptable or compatible 
carrier. The biologically active agent can act to inhibit or 
enhance eicosanoid-mediated immune responses. The agent 
is also preferably long-acting and orally active. An effective 
immunoregulatory amount of the biologically active agent 
which results in a change in the immune response of the 
invertebrate can be determined by the method provided in 
the present invention. 
Agents which can inhibit eicosanoid biological activity 
include antagonists of prostaglandins, leukotrienes and 
arachidonic acid, altered intermediates or enzymes of 
eicosanoid biosynthetic pathways, inhibitors of Signal mol 
ecules which turn on eicosanoid biosynthesis, and, 
preferably, inhibitors of the eicosanoid biosynthetic path 
way. Agents which can enhance or Stimulate invertebrate 
eicosanoid biological activity include agents which Stimu 
late the enzymes of eicosanoid biosynthetic pathway, altered 
enzymes of the eicosanoid biosynthetic pathway, agents 
which Stimulate Signal molecules which turn on eicosanoid 
biosynthesis, inhibitors of eicosanoid inactivating enzymes 
like dehydrogenases and reductases, and preferably 
prostaglandins, leukotrienes, arachidonic acid and analogs 
thereof. Alternatively, the biologically active agent can be a 
genetically engineered organism, preferably an invertebrate 
pathogen, which expresses, Secretes and delivers an agent 
which alters eicosanoid biological activity. 
The biologically active agent is Substantially Soluble or 
dispersible in a Suitable carrier which functions to assist 
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delivery of the agent to the appropriate Site. The carrier is 
physiologically acceptable or compatible with living organ 
isms including invertebrates, plants, fish, and other verte 
brates. The composition can further be comprised of a 
Surface-active agent which increases adherence and/or pen 
etration of the biologically active agent to the target Site. 
The pharmaceutical composition is administered in an 
effective immunoregulatory amount to an invertebrate 
organism by feeding by injecting or preferably by Spraying 
the invertebrate Species and/or its food or water Source. An 
effective immunoregulatory amount is that amount of the 
biologically active agent which results in a change in the 
immune response. Accordingly, the composition can be used 
to treat invertebrate Species to enhance or inhibit immune 
response capabilities of the organism. 
The invention also provides a biopesticide formulation 
and method of using the biopesticide formulation to control 
or eradicate invertebrate pests. The biopesticide composition 
is comprised of an effective pesticidal amount of at least one 
biologically active agent which inhibits eicosanoid 
mediated immune responses of an invertebrate organism and 
a physiological compatible carrier. An effective pesticidal 
amount is that amount of the biologically active agent which 
inhibits eicosanoid-mediate immune response Sufficiently to 
cause an increase in the mortality of the invertebrate organ 
ism. Accordingly, the invention provides for a method of 
using the biopesticide composition to control the growth of 
or eradicate invertebrate pests. 
Biologically Active Agents Which Modulate Invertebrate 
Eicosanoid-Mediated Immune Responses 
Biologically active agents useful in the invention can 
modulate eicosanoid-mediated immune responses in inver 
tebrates. The role, if any, of eicosanoids in invertebrate 
immune responses was not previously known. The present 
invention has identified that eicosanoids mediate immune 
responses in invertebrates, including early immune 
responses, and provides for pharmaceutical and/or biopes 
ticide compositions which can be used to modulate 
eicosanoid-mediated immune responses and alter the health 
of invertebrate Species. 
Eicosanoids are a family of biologically potent lipid acids. 
Examples of naturally occurring eicosanoids include pros 
taglandins E, F, A, B, C, D and derivatives thereof, leukot 
rienes LTA, LTB, LTC, LTD, and LTE and derivatives 
thereof, and thromboxanes A and B and derivatives 
thereof. The compounds are biosynthetically produced in 
many Species by enzymic conversion of polyunsaturated 
fatty acids. Chemical Synthesis of eicosanoid and eicosanoid 
analogs are well known in the art. See, for example, the 
Corey synthesis described in E. Corey et al. J. Am. Chem. 
Soc., 91:535 (1970), which is hereby incorporated by 
reference, which provides for the Synthesis of naturally 
occurring PGE, PGF, and intermediates which are exten 
Sively used in the Synthesis of prostaglandin analogs. 
Other chemical Syntheses of eicosanoids are reported in 
R. Kelley et al., J. Am. Chem. Soc., 95:2746 (1973); D. 
White, Tetrahedron Lett., 1753 (1976); R. Newton et al., 
Tetrahedron, 36:2163 (1980) (synthesis of prostaglandins); 
C. Sih et al., J. Am. Chem. Soc., 97:865 (1975) (prostaglandin Synthesis involving the 1,4 addition of an 
organometallic reagent to O-3 unsaturated ketone function); 
M. Hayashi et al., J. Org. Chem., 38:2115 (1973) (synthesis 
of prostaglandin D); R. Bindra et al., in ProStaglandin 
Synthesis, Academic Press, N.Y. at pages 291-330 ()1977) 
(partial synthesis of prostaglandins A, B and C); N. Porter et 
al., J. Am. Chem. Soc., 102:1183 (1980) (synthesis of 
prostaglandin endoperoxides PGH and PGH); R. Newton 
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et al., Synthesis at page 449 (1984) (synthesis of 
prostacyclins, PGIS, and thromboxanes); B. Samuelsson, 
Science, 220:568 (1983) and J. Atkinson et al., in Handbook 
of Eicosanoids, ProStaglandins and Related Lipids, Vol. 1B, 
A. Willie ed., CRC Press, Boca Raton, Fla., at pages 
175–263 (1989) (synthesis of leukotrienes and biological 
activity); and R. Bindra et al. in ProStaglandin Synthesis, 
Academic Press, N.Y. at pages 337-348 (1977) (chemical 
interconversion of different prostaglandin families), which 
are hereby incorporated by reference. 
Eicosanoid biosynthesis in vertebrate Species has been 
described in Kirk-Othmer Concise Encyclopedia of Chemi 
cal Technology, 3rd edition, at pages 714 to 719 (1984), 
which is hereby incorporated by reference. Biosynthesis of 
eicosanoids begins with the conversion of unesterified poly 
unsaturated fatty acids to arachidonic acid. Unesterified 
polyunsaturated acids can be obtained from the diet or 
alternatively from membrane phospholipids by the action of 
phospholipases. Arachidonic acid can be converted via 
enzymatic activity of cyclooxygenase to unstable 
endoperoxides, such as PGG and PGH, which can then be 
converted to prostaglandins and thromboxane S. 
Alternatively, arachidonic acid can be enzymatically con 
verted by lipoxygenase enzyme activity to form leukot 
rienes. Although not meant to be a limitation of the 
invention, it is believed that eicosanoid biosynthesis in 
invertebrates occurs via Similar enzymatic action as that of 
eicosanoid biosynthesis in Vertebrate Species. 
Eicosanoid biosynthesis in invertebrates is known to 
occur as prostaglandins and hydroxyeicosatetraenoic acids 
are present in invertebrate tissues. Precursor polyunsaturated 
fatty acids, like Omega-3 polyenoic acids, arachidonic acid, 
and eicosatrieneoic acids, are present in fatty acid and 
phospholipid populations of invertebrate Species. Inhibitors 
of prostaglandin biosynthesis, like glucocorticoids and non 
Steroidal anti-inflammatory drugs, act to prevent prostaglan 
din biosynthesis in invertebrate tissues. More Specifically, 
inhibitors of cyclooxygenase, like acetyl Salicylic acid, 
indicate the presence of cyclooxygenase activity by inhibi 
tion of prostaglandin-mediated oviposition behavior in Silk 
moths. Phospholipase inhibitors, like glucocorticoids, indi 
cate the presence of phospholipase enzymatic activity by 
inhibition of the production of arachidonic acid from mem 
brane phospholipid precursors. Inhibitors of lipoxygenase, 
like esculetin, indicate the presence of lipoxygenase enzy 
matic activity by inhibiting the eicosanoid-mediated host 
penetration behavior of the blood fluke Schistosoma man 
SOni. 
In vertebrate Species, eicosanoid biosynthesis is initiated 
by a membrane-mediated event, like phagocytosis or bind 
ing of an antigen to receptors, which can trigger an influx of 
calcium ions, a transient increase in cyclic adenosine mono 
phosphate (cAMP), activation of phospholipases with cleav 
age of arachidonic acid from phospholipids, and conversion 
of arachidonic acid to prostaglandins and thromboxanes via 
cyclooxygenase catalyzed oxidation, and to leukotrienes via 
enzymatic action of a lipoxygenase in the cell. The newly 
Synthesized proStaglandins, thromboxanes and leukotrienes 
can be Secreted by the cell and act to mediate Stimulation of 
chemotaxis, chemokinesis, phagocytosis, and adherence 
responses of neutrophils and macrophages. Although not 
meant to be a limitation on this invention, it is believed that 
initiation of eicosanoid biosynthesis in invertebrates could 
occur in a similar manner. 
Little is known about the Spectrum of biological activity 
of eicosanoids in invertebrate species. Eicosanoids have 
been identified in a wide variety of invertebrates including 
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Sponges, echinoderms, arthropods, mollusks, and rotifers. 
Eicosanoids can mediate egg-laying behavior in crickets, 
hatching of barnacles, egg production in Snails, Spawning 
behavior of abalone, spawning behavior of the Pacific 
oyster, Osmoregulation and water transport in Modiolus 
demissuSS, host skin penetration of blood flukes, and evasion 
of host defense mechanisms by SchistoSoma manSOni. A 
more detailed description of these functions of eicosanoids 
in invertebrate species is provided by D. Stanley-Samuelson 
et al., in Progress in Comparative Endocrinology, Wiley 
Liss Inc., at pages 614-619 (1990), which is hereby incor 
porated by reference. 
It was not previously known whether eicosanoids mediate 
immune responses in invertebrates. Invertebrate immune 
response Systems are not well characterized and may func 
tion significantly differently from that of the vertebrate 
Species. Although not meant to be a limitation of the 
invention, it is believed that eicosanoids mediate immune 
responses in invertebrates and provide for pharmaceutical 
and/or biopesticide compositions which can modulate 
eicosanoid-mediated immune responses. 
The biologically active agents of the invention are those 
which modulate immunoregulatory eicosanoid biological 
activity in invertebrates. The biologically active agent which 
modulates immunoregulatory eicosanoid biological activity 
in invertebrates can be selected from the group of com 
pounds known to modulate vertebrate eicosanoid biological 
activity and tested in invertebrates to determine whether and 
what amount of the biologically active agent modulates 
invertebrate immune responses. Alternatively, the biologi 
cally active compound can be a novel compound which 
modulates eicosanoid-mediated immune response in inver 
tebrates. A modulation in the invertebrate immune response 
is determined in the method provided in the invention by 
detecting an increase or decrease in the growth of an 
infectious agent in the invertebrate Species in comparison to 
untreated control population of the invertebrate Species. 
Agents which inhibit invertebrate eicosanoid-mediated 
immune responses can provide for an increase in Suscepti 
bility to disease and an increase in mortality. Agents which 
enhance or Stimulate invertebrate eicosanoid-mediated 
immune responses can provide for a decrease in Suscepti 
bility to infectious disease and a decrease in mortality of the 
invertebrate Species. The biologically active agent can also 
be one which acts primarily to modulate eicosanoid 
mediated immune response without modifying or altering 
other biological functions of the invertebrate. The biologi 
cally active agent is preferably one which has long duration 
and is orally active. 
An effective amount of the biologically active agent 
depends in part on the type of invertebrate Species, the size 
of the invertebrate, the method of administration, and the 
type of biologically active agent. Routes of administration 
can include absorption of the agent through skin and exterior 
Surfaces of the invertebrate species, ingestion of the agent 
through the mouth or gills including from a food or water 
Source, and injecting the biologically active agent. The route 
of administration chosen will depend on the type of inver 
tebrate Species and the Stage of the life cycle when the 
biologically active agent is administered. For example, when 
the compositions of the invention are administered to the 
larval Stage, the route of administration is preferably by 
ingestion of the compositions of the invention in combina 
tion with food or water Source. The compositions can also be 
administered to larvae by absorption through skin and 
exterior Surfaces as many larvae Soft external Surfaces than 
the adult Stage exoskeletons, cuticles, or shells. If the 
6,099,834 
invertebrate is an adult crustacean, the compositions are 
preferably administered via ingestion including ingestion 
with a food Source. The composition is preferably admin 
istered to agricultural pests by Spraying the affected plants 
followed by ingestion of the plant tissues coated with the 
compositions of the invention. Methods of administration 
suitable for particular invertebrates are well known in the 
art, Some of which are described in R. Samson in Funda 
mental and Applied Aspects of Invertebrate Pathology, Pro 
ceedings of Fourth International Colloquium of Invertebrate 
Pathology at pages 597–687, the disclosure of which is 
hereby incorporated by reference. 
An effective amount for the particular invertebrate Species 
is preferably that amount of the biologically active agent 
which results in a change in the immune response. The 
change in the immune response for a particular invertebrate 
Species can be identified by an increase or decrease in 
Susceptibility of the invertebrate species to an infectious 
agent and can be determined by the method provided in the 
invention. Preferably, dosages can range from about 1x10 
Aug/gm body weight to 1x10 ug/gm body weight, and more 
preferably, about 1x10 ug/gm body weight to 1x10 
tag/gm body weight, and most preferably, about 1x10" 
tug/gm body weight to 1 lug/gm body weight 
Examples of agents which modulate eicosanoid-mediated 
immune response are those which alter formation and/or 
biological activity of the eicosanoids. These agents include 
agents that affect Signal molecules which turn on eicosanoid 
biosynthesis, agents which modify the eicosanoid biosyn 
thesis and/or formation, and agents which modify 
eicosanoid biological action. Agents that affect Signal mol 
ecules can include agents which modulate the levels of 
cAMP or Ca' ions, or those which modulate the activity of 
the phospholipases and protein kinases. Agents which alter 
or modify eicosanoid formation or biosynthesis can include 
altered enzymes of eicosanoid biosynthetic pathways, 
altered intermediates of eicosanoid biosynthetic pathways, 
Specific active site inhibitors of eicosanoid biosynthetic 
enzymes, and other competitive and non-competitive inhibi 
tors of eicosanoid biosynthesis. Agents which modify 
eicosanoid biological action can include eicosanoid analogs, 
eicosanoid antagonists, eicosanoid agonists, inhibitors of 
inactivating enzymes like inhibitors of eicosanoid dehydro 
genases and reductases, and agents which interfere with the 
release of eicosanoids from cells. The eicosanoid analogs 
can be modified to enhance selectivity for invertebrate 
immune responses. Eicosanoid analogs can also preferably 
be modified to have longer duration, to act orally, and to 
have increased potency over naturally occurring 
eicosanoids. 
The biologically active agent can also be a genetically 
engineered organism which expresses, Secretes and delivers 
a biologically active agent which alters or modulates 
eicosanoid-mediated immune response in invertebrates. 
Biologically Active Agents Which Inhibit Eicosanoid 
Mediated Immune Responses 
Biologically active agents useful in the pharmaceutical 
and/or biopesticide compositions inhibit eicosanoid biologi 
cal activity and provide for an inhibition of immune 
responses and an increase in Susceptibility to disease. The 
inhibitors can also provide for an increase in mortality which 
can result from inability to clear an infection with opportu 
nistic and other invertebrate pathogens, an inability to com 
pletely repair wounds, and an increase in Susceptibility to 
cancer. The inhibitors can be modified to selectively modu 
late the immune responses. The inhibitors are preferably 
long-acting and orally active. 
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Inhibitors can include antagonists of prostaglandins, 
leukotrienes, and arachidonic acid, inhibitors of the enzymes 
of the eicosanoid biosynthetic pathway, altered intermedi 
ates or enzymes of eicosanoid biosynthetic pathways, inhibi 
tors of release of prostaglandins, leukotrienes and throm 
boxanes from cells, and inhibitors of Signal molecules which 
turn on eicosanoid biosynthesis. Preferably, the biologically 
active agent is an inhibitor of the enzymes of the biosyn 
thetic pathway, and more preferably, the inhibitor is a 
peptide which blocks the active Side of an enzyme in the 
eicosanoid biosynthetic pathway. 
Examples of inhibitors of eicosanoid biosynthesis include 
cinnamic acid and derivatives thereof, arachidonic acid 
derivatives, glucocorticoids, dihydroxybenzopyran ketones 
and derivatives thereof, methanoleukotrienes and deriva 
tives thereof, binapthalene derivatives, naphthalene acetic 
acid derivatives, phosphorylcholine derivatives, indole ace 
tic acid derivatives, dihydropyridine carboxylic acid 
derivatives, phenanthrene carboxylic acids and derivatives 
thereof, Salicylic acid acetate and derivatives thereof, 
neomycins, benzoxazoleacetic acids and derivatives thereof, 
and dihydroxyanthrone derivatives and mixtures thereof. 
Specific examples of inhibitors of eicosanoid biosynthesis 
include inhibitors of the eicosanoid biosynthetic enzymes: 
phospholipase A2, cyclooxygenase, 5-lipoxygenase, 
12-lipoxygenase, and 15-lipoxygenase. Inhibitors of 
cyclooxygenase include Eb Selen (2-phenyl-1,2- 
benzisoselenazol-3(2H)-one), curcumin, ETYA (5,8,11,14 
eicosatetraynoic acid), naproxen, indomethacin, nonsteroi 
dal anti-inflammatory drugs Such as Salicylic acid acetates 
and derivatives thereof, phenidone, benoxaprofen, and REV 
5741. Inhibitors of phospholipase include phosphorylcho 
line and derivatives thereof, glucocorticoids, DEDA (7,7- 
dimethyl-eicosadienoic acid), neomycins and derivatives 
thereof, aminocephalosporanic acid and derivatives thereof, 
chlorpromazine HCl and derivatives thereof, dihydropyri 
dine carboxylic acid and derivatives thereof, manoalide, 
phenanthrene carboxylic acids and derivatives thereof, and 
compound 48/80. Inhibitors of lipoxygenase enzymes 
include 5-lipoxygenase inhibitors: Ebselen, REV-5901 (2- 
3(1-hydroxy hexyl)phenoxy methylquinoline 
hydrochloride), REV-5367, REV-5747, REV-5827, REV 
5875, REV-5965, REV-6080, 12-lipoxygenase inhibitors: 
REV-5747, REV-5827, and REV-5901, 15-lipoxygenase 
inhibitors: REV-5367 and phenidone (1-phenyl-3- 
pyrazolidinone); and other lipoxygenase enzyme inhibitors 
including: anthralin, Baicalein (5,6,7-trihydroxyflavone), 
caffeic acid, curcumin, cinnamic acid and derivatives 
thereof, arachidonic acid derivatives, DEDA, dipyridamole, 
ETI (5,8,11-eicosatriynoic acid), esculetin, gossypol, 
indomethacin, NDGA (nordihydroguaiaretic acid), 
phenidone, benoxaprofen, methanoleukotrienes and deriva 
tives thereof, AA-861 (2-(12-hydroxy-5,10-dodecadiynyl)- 
3,5,6-trimethyl-p-benzoquinone), nafazatrom, and querce 
tin. 
Inhibitors can include antagonists and/or agonists of 
prostaglandins, leukotrienes and arachidonic acid. These 
inhibitors can prevent the biological action of eicosanoids by 
binding to receptorS and active Sites of enzymes and/or 
preventing release of eicosanoids from cells. Specific 
examples of these agents include the eicosanoid antagonists 
13-APA (13-aZaprostanoic acid), carbacyclin, CTA 
(carbocyclic thromboxane A2 (CAS Registry No. 74034 
56-3)), U-44069 (9,11-dide oxy-11 - C.-9- C.- 
epoxymethanoprostaglandin F2C), U-46619 (cromolyn), 
DSCG ((15S)-15-hydroxy-11-C-9-C-(epoxymethano) 
prosta-5(Z), 13(E)dienoic acid), Oxatomide, PTA (pinane 
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thromboxane A2), Xanthines and derivatives thereof, and 
mixtures thereof. 
Inhibitors can include inhibitors of Signal transduction 
molecules. Signal transduction molecules include calcium 
ions, phospholipases, cyclic AMP, and protein kinases. Spe 
cific examples of Such inhibitors include A-3, erbstatin, 
genistein, H-7, K-252a, phloretin, Sphingosine, StauroSporin, 
calcium channel blockers, glucocorticoids, and mixtures 
thereof. 
Altered intermediates of eicosanoid biosynthesis are ana 
logs of prostaglandins, leukotrienes and thromboxanes 
which compete with naturally occurring eicosanoid inter 
mediates and inhibit the biosynthetic enzyme activity, 
thereby inhibiting production of eicosanoids. Altered inter 
mediates are not active and can be formed by a modification 
of the Structure of eicosanoids, including modification of 
carbon-15, the carboxylic acid Sidechain and the aliphatic 
Sidechain of prostaglandins, B-Cs. Sidechain of prostaglan 
dins and thromboxanes, and the 2,6-diaxobicycloheptane 
skeleton of thromboxanes. 
Altered enzymes of the eicosanoid biosynthetic pathway 
include derivatives of phospholipase A, cyclooxygenase, 
5-lipoxygenase, 12-lipoxygenase, and 15-lipoxygenase. The 
altered enzymes which Serve as inhibitors of eicosanoid 
mediated immune response are inactive enzymatically and 
bind to the intermediates in eicosanoid biosynthesis. The 
altered enzymes compete with the naturally occurring 
enzymes by binding intermediates in the biosynthesis, but 
Since the altered enzymes are enzymatically inactive, 
eicosanoid biosynthesis cannot proceed, thereby inhibiting 
production of eicosanoids. Altered enzymes which are inac 
tive can be formed by modification of the amino acid 
Sequence of the enzyme and preferably, the amino acid 
Sequence of the active Site of the particular eicosanoid 
biosynthetic enzyme is altered. 
The biologically active agent which inhibits eicosanoid 
mediated immune responses is Substantially Soluble or dis 
persible in the carrier. The inhibitor is combined with the 
carrier in an effective amount to form a pharmaceutical 
composition. The types of and effective amounts of the 
inhibitor are those agents and amounts which inhibit 
immune responses in the invertebrate Species as determined 
by an increase in the growth of an infectious agent in the 
invertebrate Species in comparison to the untreated control 
population. 
Biologically Active Agents Which Enhance Eicosanoid Bio 
logical Activity 
Biologically active agents which Stimulate or enhance 
eicosanoid-mediated immune responses can provide for a 
decrease in the Susceptibility to disease, including infectious 
disease. The Stimulating agents can also provide for a 
decrease in the mortality. The Stimulating agents can be 
modified to more Selectively modulate immune responses. 
Preferably the Stimulating agents are long-acting and orally 
active. 
Agents which can enhance or Stimulate invertebrate 
eicosanoid-mediated immune response include 
prostaglandins, leukotrienes, arachidonic acid and analogs 
thereof, agents which Stimulate the enzyme of eicosanoid 
biosynthetic pathways, altered enzymes of the eicosanoid 
biosynthetic pathway, and agents which Stimulate Signal 
molecule which turn on eicosanoid biosynthesis. Preferably, 
the biologically active agent is an analog of a prostaglandin, 
leukotriene, or arachidonic acid, and more preferably an 
analog which is orally active, has prolonged duration of 
biological activity, and increased potency when compared 
with naturally occurring eicosanoids. 
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Specific examples of Simulators of eicosanoid biosynthe 
sis include omega group fatty acids, phospholipases and 
derivatives thereof, calcium ionophors, eicosanoid biosyn 
thetic enzymes and derivatives thereof, eicosanoid biosyn 
thetic intermediates, arachidonic acids and derivatives 
thereof, and mixtures thereof. Omega group fatty acids and 
arachidonic acid and derivatives thereof provide precursors 
for eicosanoid biosynthesis. Eicosanoid biosynthetic 
enzymes include phospholipases, cyclooxygenases, and 
lipoxygenases. Agents which provide Signal molecules 
include phospholipases and calcium ionophors. 
Altered biosynthetic enzymes are derivatives of phospho 
lip a Se A2, cyclooxygenase, 5-lip OXygenase, 
12-lipoxygenase, and 15-lipoxygenase enzymes. The altered 
enzymes are enzymatically active and can function in 
eicosanoid biosynthetic pathways. Alterations can be made 
to the amino acid Sequences of the enzyme and preferably 
alterations are made to the amino acid Sequence of the active 
Site of the eicosanoid biosynthetic enzymes. 
Preferably the biologically active agent is an analog of 
prostaglandins, leukotrienes or arachidonic acid, and more 
preferably an analog which is orally active, has prolonged 
duration of biological activity, and increased potency in 
invertebrates. Analogs are formed by Synthetic modification 
of the chemical Structure of eicosanoids. Modifications to 
carbon-15, the carboxylic acid Sidechain and the aliphatic 
Sidechain of prostaglandins, the B-Cs. Sidechain of proStag 
landins and thromboxanes, and the 2,6-diaxobicycloheptane 
skeleton of thromboxanes can result in a longer-acting, 
orally active, and more potent analogs. Modification of 
eicosanoids at the Sites can also provide an analog which 
acts Substantially Selectively to modulate invertebrate 
immune responses. Specific examples of longer-acting and 
orally active analogs of eicosanoids include 15(R)-15 
methyl PGE, 11(R)-11-deoxy-11,16,16-trimethyl-PGE, 
dl-4,5-didehydro-16-phenoxy-17, 18,19,20-tetranor-PGE 
methyl ester, d1-(11R,15RS)-11, 15-dihydroxy-15-methyl-9- 
OXO-13-thiaprostanoic acid p-benzamidophenylester, dil 
(15RS)-15-deoxy-16-hydroxy-16-vinyl-PGE methyl ester, 
and mixtures thereof. 
The biologically active agent which Stimulates 
eicosanoid-mediated immune responses is Substantially 
Soluble or dispersible in the carrier. The Stimulating agent is 
combined with the carrier in an effective amount to form a 
pharmaceutical composition. The types and effective 
amounts of Stimulating agents are those agents and amounts 
which enhance immune responses in the invertebrate Species 
as determined by a decrease in the growth of an infectious 
agent in comparison to untreated control population. 
The pharmaceutical composition is administered to inver 
tebrate Species to enhance immune responses and decrease 
Susceptibility of the invertebrate to disease, including infec 
tious disease. The Stimulating agent can also provide a 
decrease in mortality by increasing resistance to infectious 
disease, enhancing wound repair, and increasing resistance 
to cancer. Accordingly, the pharmaceutical composition can 
be used in prophylaxis and treatment of disease, including 
infectious disease, in commercially important invertebrate 
Species. 
Biologically Active Agents Which Are Genetically Engi 
neered Organisms 
The biologically active agent can also be a genetically 
engineered organism which expresses, Secretes and delivers 
an agent which alters or modulates eicosanoid-mediated 
immune responses to invertebrates. The agent which alters 
eicosanoid-mediated immune responses can be one that 
enhances or inhibits immune responses in invertebrates. For 
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example, the agent may be a peptide which inhibits an active 
Site of eicosanoid biosynthetic enzyme or an altered 
eicosanoid inactivating enzyme. 
Suitable organisms include genetically engineered yeast, 
bacteria, Viruses, plants or fungi. Preferably the organism is 
a microorganism which can infect and grow in the particular 
invertebrate Species and, more preferably, a pathogenic 
microorganism. Genetically engineered pathogens of the 
invention can invade and produce disease in invertebrate 
Species as well as deliver inhibitors of eicosanoid-mediated 
immune responses. 
Genes can be cloned and introduced into the organisms by 
standard recombinant DNA methods. Such techniques are 
well known to those of skill in the art and are outlined in 
Guide to Molecular Cloning Techniques. Methods in 
Enzymology, Vol. 152, S. Berger and A. Kimal, ed., Aca 
demic Press, Inc., San Diego, Calif. (1987), which is hereby 
incorporated by reference. Genes can be introduced into 
cells by vector-mediated transformation with vectors like 
Viruses and plasmids, or by physical methods of transfor 
mation including use of microprojectiles, microinjection, 
biolistic transformation, electroporation, incubation with 
calcium-precipitated DNA, and incubation with liposomes 
containing foreign DNA. See M. Fromm et al., PNAS, 
82:5824 (1984) (electroporation); T. M. Klein et al., Nature, 
327:70 (1987) (microprojectiles); P. Lurquin et al., Plant 
Science Lett., 25:133 (1982) (liposomes), the disclosures of 
which are hereby incorporated by reference. 
Genes which can be introduced into organisms as a Single 
gene or a cassette containing multiple genes. For example, 
an expression cassette can include genes for Selective mark 
erS like antibiotic resistance as well as genes encoding one 
or more biologically active agents which inhibit or enhance 
eicosanoid-mediated immune responses. Genes encoding 
the biologically active agents can be modified to provide for 
enhanced expression and/or Secretion of the biologically 
active agent from the microorganism. Genes can also be 
hybrid genes with one DNA sequence encoding a transit 
peptide which allows for targeting and transport of the 
remainder of the molecule to the invertebrate target cell, and 
a Second DNA sequence encoding at least one biologically 
active agent to be delivered to the invertebrate target cell. 
Specific examples of genes which can be used to trans 
form organisms, either alone or as a part of an expression 
cassette, include genes encoding eicosanoid biosynthetic 
enzymes and mutants thereof, genes encoding eicosanoid 
inactivating reductase and dehydrogenase enzymes and 
mutants thereof, genes encoding altered Signal transduction 
molecules and mutants thereof, and genes encoding peptide 
inhibitors of the active sites of eicosanoid biosynthetic 
enzymes and mutants thereof. 
In a preferred version, an invertebrate pathogenic agent, 
as for example, Serratia marceScens, is transformed with the 
gene encoding a peptide which blockS or inhibits the active 
Site of an eicosanoid biosynthetic pathway enzyme. The 
pathogenic agent is transformed with a plasmid vector also 
containing a Selectable marker or reporter gene. The trans 
formed pathogen is Selected using the Selectable marker or 
reporter gene and expresses, Secretes and deliverS Sufficient 
amount of the peptide inhibitor to the invertebrate Species to 
provide an inhibition of the immune response. 
The genetically transformed organism is Substantially 
Soluble or dispersible in the carrier. The genetically engi 
neered organism is combined with the carrier in an effective 
amount to form a pharmaceutical and/or biopesticide com 
position. An effective amount of genetically engineered 
organism is that amount which alters or modulates the 
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invertebrate Species immune responses. A genetically engi 
neered non-pathogenic organism which infects and grows, 
can deliver immunostimulating agents to commercially 
valuable invertebrate Species. The preferred version pro 
vides for a genetically engineered pathogen which can Serve 
as a biopesticide for a particular invertebrate pest. 
Method for Determining Whether and What Amount of the 
Biologically Active Agent Is Effective to Modulate Immune 
Responses in Invertebrates 
The invention provides a method for determining whether 
and what amounts of the biologically active agent result in 
a change in immune responses of the particular invertebrate 
Species. The method involves administering different dos 
ages of the biologically active agent in the carrier to the 
particular invertebrate Species followed by inoculation of the 
invertebrate with an effective amount of an infectious agent, 
preferably a pathogen. A control group of organisms 
receives the carrier alone followed by inoculation with the 
infectious agent. After an effective incubation period to 
provide for Sufficient growth of the infectious agent, pref 
erably about 0.5 hours to 10 hours post-infection and more 
preferably about 1–5 hours post-infection, tissue or 
hemolymph samples are withdrawn from the invertebrate 
organism, extracted in physiological Solution, and incubated 
with growth medium. Suitable physiological Solutions 
include physiological Salt Solutions of Sodium chloride, 
Sodium phosphate, and Sodium citrate. The growth medium 
is incubated until Sufficient growth of the infectious agent 
occurs, and the amount of infectious agent present in the 
Sample is determined. A change in the immune response is 
determined by comparing the amount of infectious agent 
recovered from the tissue samples from the invertebrate 
organisms receiving different doses of the biologically 
active agent with the amount of infectious agents recovered 
from control organisms. An increase or decrease in the 
amount of infectious agent recovered from organisms 
treated with the biologically active agent, and preferably, an 
increase or decrease at least about 2-fold, indicates a change 
in the immune response. An effective immunoregulatory 
amount can be calculated by determining which dosages of 
the biologically active agent result in a change in the 
immune response. 
In a preferred version, an invertebrate agricultural pest 
Species, as for example Manduca Sexta, is injected with 
different dosages of dexamethasone, an inhibitor of 
eicosanoid biosynthesis. The organism is then injected with 
a pathogenic agent for the particular invertebrate Species, 
like, for example, Serratia marceScens. The control group 
receives absolute ethanol followed by inoculation with the 
pathogenic agent. After about 1 hour post-infection, 
hemolymph Samples are withdrawn, extracted, diluted, and 
plated on Standard method agar plates to provide for growth 
of the pathogenic agent. Serratia marceScens colonies are 
incubated for 40–48 hours to provide for sufficient bacterial 
growth. AS the dosage of the inhibitor is increased, the 
amount of pathogenic agent recovered from the tissue is 
determined. The lower doses of the inhibitor resulting in 
about 2-fold increase in the amount of the recovered bacteria 
and higher doses result in at least about a 20-fold increase 
over the amount of bacteria recovered from the control. An 
increase of at least about 2-fold in the amount of the 
pathogenic agent recovered from tissue samples of inverte 
brates treated with the inhibitor indicates an inhibition in the 
immune response. 
Infectious agents useful in the method are those which can 
infect and grow in a particular invertebrate Species, and are 
preferably pathogenic microorganisms. Suitable infectious 
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agents and effective amounts for a particular invertebrate 
Species to be tested in the method are known to those of Skill 
in the art and are outlined in A. Sparks in Synopsis of 
Invertebrate Pathology, Elsevier, at pages 133-382 (1985) 
and in R. Samson et al. in Fundamental and Applied Aspects 
of Invertebrate Pathogens, Proceedings of the Fourth Inter 
national Colloquium of Invertebrate Pathology, at pages 
1-362 (1986), the disclosures of which are hereby incorpo 
rated by reference. Appropriate growth medium and growth 
conditions to recover the infectious agent from the tissue 
samples of the invertebrate are known to those of skill in the 
art. 
The dosage range of the biologically active agent admin 
istered in the method depends on the size of the invertebrate, 
the type of biologically active agent, and the method of 
administration. Preferably, different dosages ranging from 
about 1x10 ug/gm body weight to 1x10 ug/gm body 
weight, and more preferably, about 1x10 ug/gm body 
weight to 1x10 ug/gm body weight, and most preferably, 
about 1x10" ug/gm body weight to 1 lug/gm body weight 
can be administered to the invertebrate Species to determine 
whether and what amounts of the particular biologically 
active agent modulate eicosanoid-mediate immune 
responses in the particular invertebrate Species. 
Carriers 
The biologically active agent is combined with a Suitable 
carrier which functions to assist delivery of the agent to the 
appropriate Site. The choice of carrier depends on the habitat 
of the invertebrate, type of food consumed by the 
invertebrate, and the physical characteristics of the biologi 
cally active agent. The biologically active agent is Substan 
tially Soluble or dispersible in the carrier, and the carrier is 
Substantially physiologically acceptable or compatible with 
invertebrates, plants, fish, and other vertebrate organisms. 
The carrier can function to help the biologically active agent 
adhere to plant leaves and other food Sources consumed by 
the targeted invertebrate species. The carrier can also func 
tion to allow the biologically active agent to adhere and/or 
penetrate the external skeletons, tests, shells, or cuticles of 
invertebrate species. The carrier can also be a food Source 
for the invertebrate Species like plant leaves or brine Shrimp. 
The carrier can be formulated into a liquid or powder or 
granular mixture for Spray delivery or micro encapsulated in 
liposomes and the like. For example, a pharmaceutical 
composition Suitable for aerial Spraying can include an 
effective amount of biologically agent mixed with dried 
quart Sand and vegetable oil. Specific examples of Suitable 
carriers include paraffin wax, lecithins, vegetable oil, Saline 
Solutions, Salt Solutions, absolute ethanol, corn grits, Sand, 
phospholipids, Sustained release polymers and mixtures 
thereof. In a preferred version, the biologically active agent 
is dissolved in absolute ethanol and mixed with soybean 
lecithin and paraffin wax. 
Sustained release polymers are those polymers that can 
incorporate the biologically active agent of the invention and 
provide for controlled release or delivery of the biologically 
active agent. Sustained release polymers can be formulated 
to provide for micro or macro encapsulation of the biologi 
cally active agent. Examples of Suitable Sustained release 
polymers are hydrogels, acrylates, polylactides, polyacrylic 
acids, polyethylene glycols, polyglycolides, and polymers 
with leachable occluded Substances and mixtures thereof. 
The carrier of the composition can be further comprised 
of a Surface active agent. The Surface active agent readily 
disperses in the carrier and increases the adherence and/or 
penetration of the carrier and biologically active agent to a 
target Site. Suitable Surface active agents include anionic 
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Surface agents, cationic Surface agents, nonionic Surface 
agents, and ampholytic Surface active agents. 
Surface active agents are present in the carrier in amounts 
effective to decrease Surface tension, increase wettability, 
increase adherence to the target Site, and increase penetra 
tion of the biologically active agent. Specific examples of 
the Surface active agents are provided in Adjuvants for 
Herbicides, published by Weed Science Society of America, 
R. Hodgson, ed., at Chapter 8, pp. 119-137 (1982), the 
disclosure of which is hereby incorporated by reference. 
The carrier can also include additives that enhance Sta 
bility of and absorption of the biologically active agents. 
Additives, Such as antioxidants and UV protectants, increase 
Stability of the biologically active agents exposure to Sun 
and oxygen. Additives which can assist in absorption of the 
biologically active agents can include propylene glycol, 
glycerol, urea, Sodium lauryl Sulfate, Sorbitan ethoxylates, 
oleic acid, n-methyl pyrrolidone, dimethyl Sulfoxide and 
mixtures thereof. 
Biopesticide Composition 
Biologically active agents which inhibit eicosanoid 
mediated immune responses of the present invention are 
capable of functioning as biological pesticides either alone 
or in combination with other pesticides. A pest management 
Strategy can involve combining chemical pesticides, bio 
logical pesticides, and the biopesticide inhibitors of the 
present invention to provide for control eradication of target 
invertebrate Species. 
Agents which can inhibit invertebrate eicosanoid 
mediated immune responses can include antagonists of 
prostaglandins, leukotriene, and arachidonic acid, inhibitors 
of the eicosanoid biosynthetic pathway, altered intermedi 
ates and/or altered enzymes of the eicosanoid biosynthetic 
pathways, and inhibitors of Signal molecules which turn on 
eicosanoid biosynthesis. The inhibitor can be long-acting 
and orally active. Preferably, the biologically active agent is 
an inhibitor of the enzymes of the eicosanoid biosynthetic 
pathway, and more preferably, the inhibitor is a peptide 
which blocks the active site of an enzyme in the eicosanoid 
biosynthetic pathway. 
The biologically active agent can also be a genetically 
engineered organism which expresses, Secretes and delivers 
an agent which inhibits eicosanoid-mediated immune 
responses of the invertebrate Species. Suitable organisms 
can be genetically engineered yeast, bacteria, Viruses, plants, 
or fungi. The organism is preferably a microorganism which 
can infect and grow in the particular invertebrate Species and 
more preferably a microorganism or pathogenic microor 
ganism. Genes are cloned and introduced into the organism 
by standard recombinant DNA methods and include genes 
encoding the enzyme of the eicosanoid biosynthetic pathway 
and mutants thereof, genes encoding altered Signal trans 
duction molecules and mutants thereof, and genes encoding 
peptides which block the active sites of the enzymes of the 
eicosanoid biosynthetic pathway. In a preferred version, a 
pathogenic bacteria, like Serratia marceScens, is trans 
formed with a plasmid containing a gene encoding a peptide 
which blocks or inhibits the active site of an enzyme of the 
eicosanoid biosynthetic pathway, like phospholipase A. 
An effective pesticidal amount of the biologically active 
agent depends in part on the invertebrate Species, the size of 
the invertebrate, the method of administration, and the type 
of biologically active agent. An effective biopesticidal 
amount is that amount of the inhibitor which sufficiently 
inhibits eicosanoid-mediated immune response in the inver 
tebrate to provide an increase in mortality of the invertebrate 
Species and can be determined by the method of the inven 
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tion. Suitable dosage ranges can include about 1x10 
Aug/gm body weight to 1x10 ug/gm body weight, and more 
preferably, about 1x10 ug/gm body weight to 1x10 
Aug/gm body weight, and most preferably, about 1x10' 
tug/gm body weight to 1 lug/gm body weight. The invention 
also provides a method for determining which biologically 
active agents and what amounts are effective to control the 
growth of the particular invertebrate species. 
The biologically active agent is combined with a Suitable 
carrier which functions to assist delivery of the agent to the 
appropriate Site. The choice of carrier depends on the habitat 
of the invertebrate, type of food consumed by the 
invertebrate, and the physical characteristics of the biologi 
cally active agent. The biologically active agent is Substan 
tially Soluble or dispersible in the carrier, and the carrier is 
Substantially physiologically acceptable or compatible with 
invertebrates, plants, fish, and other vertebrate organisms. 
The carrier can function to help the biologically active agent 
adhere to plant leaves and other food Sources consumed by 
the targeted invertebrate species. The carrier can also func 
tion to allow the biologically active agent to adhere and/or 
penetrate the external skeletons, tests, shells, or cuticles of 
invertebrate species. The carrier can also be a food Source 
for the invertebrate Species like plant leaves or brine Shrimp. 
The carrier can be formulated into a liquid or powder or 
granular mixture for Spray delivery or micro or macro 
capsules. Suitable carriers include paraffin wax, lecithins, 
vegetable oil, Saline Solutions, physiological Salt Solutions, 
absolute ethanol, corn grits, Sand, membrane phospholipids, 
Sustained release polymers, and mixtures thereof. 
The biopesticide composition can further be comprised of 
additional agents which provide for Stability and protection 
of biologically active agents from environmental conditions, 
like Sun and oxygen. Suitable agents include UV protectants 
and antioxidants. The biopesticide composition can also be 
comprised of a Surface active agent which aids in adherence 
and/or penetration of the biologically active agent. Suitable 
Surface active agents include anionic Surface agents, cationic 
Surface agents, nonionic Surface agents, and ampholytic 
Surface agents. 
Known chemical pesticides are useful in combination 
with the biopesticide compositions of the present invention 
to control or eradicate invertebrate Species. Chemical pes 
ticides are non-naturally occurring chemicals which can 
non-specifically kill invertebrate Species at all Stages of their 
life cycle. Chemical pesticides can persist in the environ 
ment and their effects are long-lasting. However, chemical 
pesticides are often not 100% effective and resistant species 
of invertebrates can arise. While not limiting the scope of the 
invention, it is believed that combining a chemical pesticide 
with the biological pesticide inhibitors of the present inven 
tion can improve efficacy of the chemical pesticide and 
eliminate resistant species, allowing for the use of lower 
doses of chemical pesticides. Specific examples of pesti 
cides currently used in invertebrate pest control are DDT, 
malathion, fenitrothion, pirimiphoSmethyl, carbamates, 
propoXur, bendiocarb, chlorphoXim, prye throids, 
permethrin, deltamethrin, and temephoS. 
Known biological pesticides are useful in combination 
with the biopesticide compositions of the present invention. 
Biological pesticides consist of naturally occurring organ 
isms which are host specific and are biodegradable and, 
thereby, minimize the environmental contamination. Bio 
logical pesticides currently in use include invertebrate 
pathogens, parasites, and predators like larvivorus fish. 
Biological pesticides are also not 100% effective against 
invertebrate Species, in part because of low virulence and 
15 
25 
35 
40 
45 
50 
55 
60 
65 
18 
limited host range. Although not meant to be a limitation of 
the Scope of the invention, it is believed that combining 
known biological pesticides with the biopesticide inhibitors 
of the present invention may help to increase virulence and 
host range by allowing pathogens and parasites to grow 
more rapidly in invertebrate Species while immune 
responses of the invertebrate species are inhibited. Examples 
of known biological control agents include Species of Bacil 
lus thuringiensis, Bacillus popilliae, Bacillus Sphaericus, 
species of Nosema, Serratia entomophila, Verticillium 
lecanii, Hirsutilla thompsonii, Metarhizum anisopliae, and 
Blauvaria bassiana. 
Inhibitors of eicosanoid-mediated immune responses use 
ful as biopesticides can be combined with one or more 
chemical or biological pesticides in a carrier to form a 
biological pesticide composition. The biopesticide inhibitors 
are compatible with the biological or chemical pesticide and 
are substantially soluble or dispersible in the mixture of 
carrier and chemical or biological pesticide. The biopesti 
cide inhibitors are present in the composition in an amount 
effective to inhibit the immune responses and provide an 
increase in the mortality of the target invertebrate Species. 
The composition can be administered by Spraying, injecting, 
painting, brushing, or Squirting in a Single or plurality of 
applications until the targeted invertebrate pest is controlled 
or eradicated. 
In a preferred version, an effective biopesticidal amount 
of the inhibitor of eicosanoid biosynthesis, like 
dexamethasone, can be combined with a known biological 
pesticide, like Bacillus thuringiensis serotype H-14, by 
mixing with a carrier of paraffin wax and Soybean lecithin. 
This composition can be administered by Spraying to inver 
tebrate pests, like mosquito larvae, of Culex pipiens, Aedes 
vexans, Aedes cantans, and Anopheles maculipennis until 
Sufficient control or eradication of the invertebrate species is 
observed. 
Method for Determining Whether and What Amounts of the 
Inhibitors of Eicosanoid-Mediated Immune Responses Are 
Useful in the Biopesticide Compositions 
The invention provides a method for determining whether 
and what amounts of the biologically active inhibitors result 
in an inhibition of the immune response Sufficient to increase 
the mortality of the invertebrate Species in response to a 
pathogenic infection. The method involves administering an 
amount of the biologically active inhibitor of eicosanoid 
mediated immune responses in the carrier to the particular 
invertebrate species followed by inoculation of the inverte 
brate with an effective amount of an infectious agent, 
preferably a pathogen, to form a test population. A control 
population of organisms receives the carrier alone followed 
by inoculation with the infectious agent. The control and test 
populations are incubated for an effective period of time to 
provide for Sufficient growth of the infectious agent, pref 
erably about 5 to 72 hours post-infection, and more prefer 
ably about 5 to 24 hours post-infection. After the incubation, 
the percentage of organisms Surviving in the test population 
is compared to the percentage of organisms Surviving in the 
control group. A decrease in the percentage of organisms 
surviving of at least about 2-fold when compared with the 
control population over the same period of time indicates 
whether and what amount of the inhibitor inhibits inverte 
brate immune responses Sufficiently to provide an increase 
in mortality. The effective biopesticidal amount of the 
inhibitor is calculated by determining which dosages of 
biologically active inhibitors result in an increase in mor 
tality. 
In a preferred version, an invertebrate agricultural pest, as 
for example Manduca Sexta, is injected with different dos 
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ages of an inhibitor of eicosanoid biosynthesis, like dexam 
ethasone. The invertebrate organism is injected with a 
pathogenic agent for the particular invertebrate Species, like, 
for example, Serratia marceScens. The control group 
receives absolute ethanol followed by inoculation with a 5 
pathogenic agent. After about 14 hours post-infection, the 
number of Surviving invertebrate organisms is counted. AS 
the dosage of the inhibitor is increased, the percentage of 
Surviving organisms decreases. The lower doses of the 
inhibitor result in about a 2-fold decrease in the percentage 10 
of organisms Surviving and higher doses result in a 4-fold 
decrease in the percentage of organisms Surviving the patho 
genic infection. A decrease of at least about 2-fold in the 
percentage of organisms Surviving the pathogenic infection 
indicates an inhibition of the immune response Sufficient to 15 
increase mortality of the invertebrate Species. 
Infectious agents useful in the method are those which can 
infect and grow in a particular invertebrate Species, and are 
preferably pathogenic microorganisms. Suitable infectious 
agents and effective amounts for a particular invertebrate 20 
Species to be tested in the method are known to those of Skill 
in the art and are outlined in A. Sparks in Synopsis of 
Invertebrate Pathology, Elsevier, at pages 133-382 (1985) 
and in R. Samson et al. in Fundamental and Applied Aspects 
of Invertebrate Pathogens, Proceedings of the Fourth Inter- 25 
national Colloquium of Invertebrate Pathology, at pages 
1-362 (1986), the disclosures of which are hereby incorpo 
rated by reference. 
The dosage range of the biologically active agent admin 
istered in the method depends on the size of the invertebrate, 30 
the type of biologically active agent, and the method of 
administration. Preferably, different dosages ranging from 
about 1x10 ug/gm body weight to 1x10 ug/gm body 
weight, and more preferably, about 1x10 ug/gm body 
weight to 1x10 ug/gm body weight, and most preferably, 35 
about 1x10" ug/gm body weight to 1 lug/gm body weight 
can be administered to the invertebrate Species to determine 
whether and what amounts of the biologically active agent 
modulate eicosanoid-mediated immune responses Suffi 
ciently to provide an increase in mortality and thus are useful 40 
in a biopesticide composition for a particular invertebrate 
Species. 
Method for Altering the Health of Invertebrate Animals With 
the Compositions Containing Biologically Active Agents 
Which Modulate Eicosanoid-Mediated Immune Responses 45 
The present invention also provides for a method for 
altering the health of invertebrate animals involving admin 
istering an effective immunoregulatory amount of a compo 
Sition containing a biologically active agent which modu 
lates eicosanoid-mediated immune responses. The 50 
biologically active agent can inhibit or enhance immune 
responses of invertebrates. The choice of the biologically 
active agent will depend on the goal of the treatment. If the 
goal of the treatment is to inhibit the growth of the inver 
tebrate Species, at least one inhibitor of eicosanoid-mediated 55 
immune responses can be included in the composition. If the 
goal is to protect invertebrate Species from injurious 
conditions, at least one enhancer or Stimulator of eicosanoid 
mediated immune responses can be included in the compo 
Sition. 60 
An effective amount of the biologically active agent 
depends, in part, on the type of invertebrate Species, the size 
of the invertebrate, the method of administration, and the 
type of biologically active agent. The route of administration 
chosen will depend on the type of invertebrate Species and 65 
the Stage of the life cycle when the biologically active agent 
is administered. For example, when the compositions of the 
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invention are administered to the larval Stage, the route of 
administration is preferably by ingestion of the compositions 
of the invention in combination with food or water Source. 
The compositions can also be administered to larvae by 
absorption through skin and exterior Surfaces as many larvae 
lack external exoskeletons, shells or cuticles. If the inver 
tebrate is an adult crustacean, the compositions are prefer 
ably administered via ingestion including ingestion with a 
food Source. The composition is preferably administered to 
agricultural pests by Spraying affected plants followed by 
ingestion of the plant tissues coated with the compositions of 
the invention by the invertebrate pest. Methods of admin 
istration Suitable for particular invertebrates are well known 
in the art, Some of which are described in R. Samson in 
Fundamental and Applied Aspects of Invertebrate 
Pathology, Proceedings of Fourth International Colloquium 
of Invertebrate Pathology at pages 597–687, the disclosure 
of which is hereby incorporated by reference. 
An effective amount for the particular invertebrate Species 
is preferably that amount of the biologically active agent 
which results in a change in the immune response. A change 
in the immune response can be identified by an increase or 
decrease in the Susceptibility of an invertebrate Species to an 
infectious agent and can be determined by the method of the 
invention. Suitable dosage ranges include about 1x10 
Aug/gm body weight to 1x10 ug/gm body weight, and more 
preferably, about 1x10 ug/gm body weight to 1x10 
tag/gm body weight, and more preferably, about 1x10" 
tug/gm body weight to 1 lug/gm body weight. 
The composition is administered by combining it with a 
food or water Source and feeding it to the invertebrate 
Species, by injection, or preferably by Spraying the compo 
Sition onto the invertebrate and/or its food or Water Source. 
The composition can be administered as a liquid, powder, 
granules, or encapsulated like, for example, in lipoSomes. 
The composition may be sprayed onto plant leaves and 
foliage or water Sources by a low-pressure backpack Sprayer, 
or by aerial spraying. The composition is delivered to the 
target invertebrate Species by ingestion, including ingestion 
of a food or water Source containing the biologically active 
agent, by penetration through the Outer Surface of the 
invertebrate body including wound penetration, and by 
injection. The composition can also be delivered by geneti 
cally engineered microorganism which, as it grows in the 
invertebrate Species, expresses, Secretes and delivers the 
biologically active agent. The composition can be adminis 
tered at all Stages if the life cycle of the invertebrate Species, 
but is preferably administered to the larval stage. The 
composition can be administered as a Single application or 
a plurality of applications until the goal of the treatment is 
achieved. 
When the invertebrate Species is an important food Source 
of commercial value, like mollusks or crustaceans, the 
invention also provides a treatment method useful to protect 
the Species from injurious conditions and/or treat disease of 
the Species. The method involves administering a pharma 
ceutical composition containing an enhancer or Stimulator of 
eicosanoid-mediated immune response in an amount effec 
tive to enhance immune responses. The enhanced immune 
response can be accompanied by an increase in the resis 
tance of the invertebrate to injurious conditions, like infec 
tious disease, and a decrease in mortality. The composition 
can be administered as granules or combined with a food 
Source, Such as brine shrimp, in a Single or a plurality of 
applications until treatment is completed. 
The method can also include administering the Stimulat 
ing agents of the present invention along with known 
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antiviral, antibacterial or antifungal agents. Suitable anti 
bacterial agents include penicillins, cephalosporins, 
Vancomycin, bacitracin, and other antibiotics. Suitable anti 
Viral agents include Vidarabine, acyclovir, ribavirin, aman 
tadine hydrochloride, interferons, and the like. Suitable 
antifungal agents include nyStatin, gentamicin, miconazole, 
and the like. 
In a preferred version, an orally active and longer-acting 
analog of a prostaglandin is combined with a food Source 
and administered to an aquaculture of a crustacean, like 
penaeid shrimp. The composition can be administered upon 
the first Signs of infectious disease or as a prophylactic 
measure in a Single or in multiple applications. 
Method for Controlling the Growth of Invertebrate Pests 
The present invention also provides a method for con 
trolling or eradicating the growth of invertebrate pests 
involving administering an effective pesticidal amount of a 
biopesticide composition until growth of the invertebrate 
Species is effectively inhibited. The biopesticide composi 
tion is composed of at least one biologically active agent 
which inhibits eicosanoid-mediated immune responses and a 
physiological compatible carrier. The choice of the biologi 
cally active agent will depend on the habitat and type of the 
invertebrate species. Suitable biologically active agents 
include those which inhibit eicosanoid-mediated immune 
responses Sufficiently to result in an increase in mortality of 
the invertebrate Species and can be determined by the 
method of the invention. 
An effective biopesticidal amount of the biologically 
active agent depends on the type of invertebrate Species, the 
Size of the invertebrate, the method of administration, and 
the type of biologically active agent. An effective biopesti 
cidal amount for the particular invertebrate species is pref 
erably that amount of the biologically active inhibitor which 
inhibits immune responses Sufficiently to result in a decrease 
of at least about 2-fold in the percentage of invertebrate 
organisms Surviving a pathogenic infection when compared 
to control invertebrates. Suitable dosage ranges include 
about 1x10 ug/gm body weight to 1x10 ug/gm body 
weight, and more preferably, about 1x10 ug/gm body 
weight to 1x10 ug/gm body weight, and most preferably, 
about 1x10" lug/gm body weight to 1 lug/gm body weight. 
The composition is administered by combining it with a 
food or water Source and feeding it to the invertebrate 
Species, by injection, or preferably by Spraying the compo 
Sition onto the invertebrate and/or its food or water Source. 
The composition can be administered as a liquid, powder, 
granules, or encapsulated like, for example, in lipoSomes. 
The composition may be sprayed onto plant leaves and 
foliage or water Sources by a low-pressure backpack Sprayer, 
or by aerial Spraying. The composition is delivered to the 
target invertebrate Species by ingestion, including ingestion 
of a food or water Source containing the biologically active 
agent, by penetration through the Outer Surface of the 
invertebrate body including wound penetration, and by 
injection. The composition can also be delivered by geneti 
cally engineering microorganism which, as it grows in the 
invertebrate Species, expresses, Secretes and delivers the 
biologically active agent. The composition can be adminis 
tered at all Stages if the life cycle of the invertebrate Species, 
but is preferably administered to the larval Stage. 
The biopesticidal composition is administered in a single 
or a plurality of applications until the growth of the inver 
tebrate species is effectively inhibited. Inhibition of growth 
of the invertebrate Species is determined by the percentage 
of invertebrate Surviving after the administration of the 
composition. An effective inhibition of growth is about 50% 
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to 100% of the invertebrate organisms dead, and preferably, 
80% to 100% of the organisms dead, and most preferably, 
95% to 100% of the organisms dead after administration of 
the biopesticide composition. 
In a preferred version, an invertebrate pest Species, like 
Manducca Sexta, is sprayed in the field with a biopesticidal 
composition containing about 50 tug/ml body weight of an 
inhibitor of an eicosanoid biosynthetic enzyme in a carrier of 
paraffin wax and Soybean lecithin. The biopesticide compo 
sition is applied until about 95% of the invertebrate pest is 
killed. 
The invention has been described with reference to vari 
ouS Specific and preferred embodiments and techniques, 
however, it should be understood that many variations and 
modifications may be made while remaining within the Spirit 
and Scope of the invention. 
EXAMPLE 1. 
Larval tobacco hornworms, Manduca Sexta, were reared 
under standard culture conditions at 28 C. under 16-hour 
light/8-hour dark photoperiod. Experiments used early fifth 
instar prewandering larvae. Test larvae were injected with 50 
tug of either the phospholipase A inhibitor dexamethasone 
(11 B, 16C.)-9-fluoro-11, 17,21-trihydroxy-16 
methylpregna-1,4-diene-3,20-dione, the cyclooxygenase 
inhibitor indomethacin 1-(p-chlorobenzoyl)-5-methoxy-2- 
methyl-3-indolyl-acetic acid, the 5- and 12-lipoxygenase 
inhibitor esculetin (6,7-dihydroxycoumarin) the nonspecific 
antioxidant maleic acid (cis-butenedioic acid), or a 1:1 
combination of indomethacin and eSculletin in 5 ul ethanol. 
Control larvae were injected with 5 ul of absolute ethanol. 
Injections were made by inserting the needle of a Hamilton 
701 Syringe dorsolaterally above the last two spiracles, 
moving the needle into the hemocell parallel to the body 
wall to avoid injuring the alimentary canal, then depressing 
the plunger. 
Three to 10 minutes after injection of inhibitors, larvae 
were infected with the pathogen Serratia marcescens by 
intrahemocoelic injection of about 5x10 bacterial cells in 
10 ul of broth, on the opposite side in the manner described 
above. After a 2.5 hour incubation at 30° C., 100 ul of 
hemolymph was withdrawn from each insect. The 
hemolymph was diluted and plated on Standard methods 
agar. The plates were allowed to dry, inverted and then 
incubated at 30° C. for 36-40 hours. Red bacterial colonies 
on each plate were then counted. In all bacterial recovery 
experiments, each agar plate represented a hemolymph 
sample withdrawn from individually identifiable larvae. 
Bacteria were recovered from Significantly more larvae 
treated with eicosanoid biosynthesis inhibitors than from 
controllarvae. S. marceScenS bacterial colonies were Seen on 
87% of the plates from dexamethasone treated larvae, 
whereas only 21% of the plates from control larvae had 
visible colonies. Larvae treated with compounds that block 
only one of the two main polyunsaturated fatty acid oxy 
genation pathways yielded intermediate results: colonies 
were recovered from about 58% of the esculetin-treated 
larvae, and from about 55% of the indomethacin-treated 
larvae. When both major pathways were inhibited simulta 
neously with indomethacin and esculetin, bacterial colonies 
were recovered from 86% of the larvae, which is nearly 
identical to the dexamethasone effect. Experiments with a 
nonspecific anti-oxidant compound maleic acid, which does 
not inhibit polyunsaturated fatty acid oxygenation pathways, 
yielded results identical to those of control larvae. Inhibition 
of eicosanoid formation with Specific inhibitors of phospho 
lipase A2, cyclooxygenase and lipoxygenase significantly 
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reduces the ability of larvae to clear pathogenic bacteria 
from their hemolymph. Inhibitors of eicosanoid biosynthesis 
inhibit the invertebrate immune response to bacterial infec 
tions. 
EXAMPLE 2 
Larval tobacco hornworms, M. Sexta, were reared as 
described in Example 1. Larva were intrahemocoelically 
injected with 50 lug of dexamethasone, a phospholipase A 
inhibitor, in 5 ul absolute ethanol. Three to ten minutes after 
injection of the inhibitors, larvae were infected with S. 
marcescens by intrahemocoelic injection of about 5x10 
bacterial cells in 10 ul of broth, on the opposite side. Control 
larvae were injected with 5 ul of absolute ethanol and then 
similarly infected with bacteria. At 15 minutes intervals 
post-infection, 15 ul of hemolymph Samples were Serially 
withdrawn from the caudal horn, diluted and plated onto 
Standard methods agar plates, and incubated for 36-40 
hours. Bacterial colonies on each plate were then counted. 
Within one hour post-infection, the dexamethasone 
treated hornworms showed an increased in bacterial growth. 
At 15 minutes post-infection, 1.8x10" colony forming units 
(CFU) of bacteria per ml of hemolymph were detected, and 
by 45 minutes post-infection, that number had nearly 
doubled to 3.3x10 CFU/ml. By 60 minutes post-infection, 
bacteria in the dexamethasone-treated worms was increased 
2.5 times that of the level of bacteria at 15 minutes post 
infection. In contrast, bacteria recovery from control horn 
worms was below 10 CFU for the first hour post-infection 
and no increase in growth of the bacteria was detected. 
These results indicate that inhibition of eicosanoid biosyn 
thesis allowed bacterial growth to begin early in the 
hemolymph and inhibited early immune responses. 
EXAMPLE 3 
M. Sexta larvae were intrahemocoelically injected with 
ethanol, or with different dosages of dexamethasone, includ 
ing 1.4x10 or 1.4x10 or 1.4x10 ug of dexamethasone 
per larvae, and then infected with 6x10 of S. marcescens. 
After a 1-hour incubation at 30° C., 100 ul of hemolymph 
was withdrawn from each insect as described in Example 1. 
The hemolymph was placed in 10 ml of dilution broth and 
0.1 ml was plated in duplicate on Standard methods agar. The 
plates were incubated, and bacterial colonies were counted 
as described in Example 1. 
Hemolymph samples from larvae treated with ethanol or 
with a lower dose of 1.4x10 ug of dexamethasone per 
larvae had a very low level of bacterial infection with 
0.35x10' CFU for the control and 0.55x10' CFU for the 
1.4x10 ug of dexamethasone-treated larvae. Larvae 
treated with higher doses of 1.4x10 ug or 1.4x10' lug of 
dexamethasone had significantly increased levels of bacte 
rial growth with 8.2x10 CFU and 10.1x10 CFU/ml of 
hemolymph, respectively. Other experiments with higher 
dosages of dexamethasone did not further increase recovery 
of bacterial colonies. Dexamethasone treatment compro 
mised the ability of hornworm larvae to clear S. marceScens 
from hemolymph in a dose-responsive manner. AS the dose 
of the inhibitor increased, an increase in bacterial growth 
was observed indicating an inhibition of the immune 
response. 
EXAMPLE 4 
M. sexta larvae were injected with 1.4x10, 1.4x10 or 
1.4x10' lug of dexamethasone per larvae, as in Example 3. 
M. Sexta larvae were also injected with 0.14 ug of dexam 
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ethasone plus 50 lug of arachidonic acid. Control larvae 
received 5 ul of absolute ethanol. The larvae were then intrahemocoelically infected with 6x10 cells of the bacteria 
S. marcescens. After 14 hours at 30° C., Surviving larvae 
were counted. Unchallenged larvae were injected with large 
doses of dexamethasone, ethanol, the cell free bacterial 
culture broth and arachidonic acid. In all cases unchallenged 
larvae Survived during the 24 hour experimental period and 
showed no adverse behavioral effects. 
The results of dexamethasone treatment on larval Survival 
show that an increase in the dose of the inhibitor resulted in 
an increase in the mortality of the invertebrate species. At 14 
hours post-infection, 46.3% of the ethanol treated control 
larvae, and 43.9% of the larvae treated with the low dose of 
1.4x10 ug of dexamethasone per larvae were alive. Larvae 
treated with higher doses of 1.4x10' ug or 1.4x10 ug of 
dexamethasone only 9.8% and 24.4% of the larvae were 
alive, respectively. 
The higher concentrations of dexamethasone greatly 
reduced the proportion of larvae that Survived pathogen S. 
marceScenS infection. The effect of the higher concentra 
tions of dexamethasone was reversed by treatment with 
arachidonic acid. At 14 hours post-infection, 45% of the 
larvae treated with both dexamethasone and arachidonic 
acid were alive when compared with 46.3% of the ethanol 
treated control larvae. In contrast, only 9.8% of the larvae 
treated with 0.14 ug of dexamethasone alone Survived. Thus, 
dexamethasone and the other inhibitors of eicosanoid bio 
Synthesis compromise the ability of the larvae to clear 
bacteria from circulation and increase mortality in the first 
24 hours post-infection. This effect is reversed by the 
presence of arachidonic acid indicating that eicosanoids 
mediate important early steps in the immune response which 
affect the survivability of the organism. 
EXAMPLE 5 
Total lipids were extracted from hemolymph and fat 
bodies from five fifth-instar larvae. Phospholipids were 
further isolated by thin-layer chromatography of the total 
lipid extract. Purified phospholipids were transmethylated 
by refluxing in acidified methanol for 1 hour at 85 C. 
Resulting fatty acid methyl esters were analyzed by gas 
chromatography and mass Spectrometry. 
Analysis of the fatty acid compositions of phospholipids 
purified from hemolymph M. Sexta larvae showed that all 
three eicosanoid precursor polyunsaturated fatty acids were 
present. These three components accounted for about 1% of 
the total phospholipid fatty acids, comparable to results from 
many other terrestrial insect species. The precursor polyun 
saturated fatty acids were composed of 20%, 20:3 (n-6), 
34% 20:4 (n-6) and 46% 20:5 (n-3). Retention times and 
mass Spectra of these compounds were exactly congruent 
with authentic Standards. Thus, all potential eicosanoid 
precursors were present in Sufficient quantities to Support 
eicosanoid biosynthesis. 
EXAMPLE 6 
Fifth instar M. sexta larvae were injected with 9.25x10 
Bq of tritiated arachidonic acid (5,6,8,9,11,12,14,15-H) 
20:4; 2.22–3.70 TBq/mmol). After 1 minute, 100 ul of 
hemolymph was collected as described in Example 1. 
Eicosanoids were extracted three times with acidified ethyl 
acetate and then Separated by thin-layer chromatography. 
Fractions were identified by cochromatography with authen 
tic unlabeled Standards and radioactivity in each fraction 
was assayed by liquid Scintillation counting on a LKB 
Wallac 1219 Rackbeta counter at 66% counting efficiency. 
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One minute after injection, 100 ul of hemolymph Samples 
were withdrawn from each of Seven larvae. In these samples, 
5.3% of the injected radioactivity (mean=2.9x10 DPM) 
was recovered. Most (95 to 97%) of the recovered radioac 
tivity was arachidonic acid. Three fractions had chromato 
graphic behavior identical to the prostaglandins PGFC, 
each PGE and PGD. A similar amount of radioactivity was 
also recovered in an otherwise uncharacterized fraction in 
the R range reported for lipoxygenase metabolites in mam 
malian Systems, presumably hydroxyeicosatetraenoic acids. 
Thus, larvae of M. Sexta were able to convert radioactive 
arachidonic acid into eicosanoids. 
EXAMPLE 7 
Healthy penaeid shrimp held in aquaculture tanks are 
injected with either 1 ug/gm body weight of PGE, PGF2, 
PGD, arachidonic acid, hydroxyeicosatetraenoic acid, 
15(R)-15 methyl-PGE2 (a PGE analog) or d1-(11R,15RS)- 
11, 15-dehydroxy-15-methyl-9-oxo-13-thioprostanoic acid, 
p-benzamidophenyl ester (a prostaglandin analog) in phos 
phate buffered saline. The shrimp are then injected with 
two-fold dilutions of Vibrio parahemaelyticus biotype algi 
nolyticus or Vibrio anquillarum and observed for the devel 
opment of clinical Signs of bacterial infection and Subse 
quent mortality. Clinical Signs of bacterial infection include 
lethargy, white discoloration of abdominal musculature, 
dorsal flexure of the abdomen, redness of periopods and 
pleopods. The ability of prostaglandins and prostaglandin 
analogs to protect the shrimp from fatal bacteremia is 
examined. Protection of the shrimp from fetal bacteremia by 
treatment with a prostaglandin or its analogs is likely. 
EXAMPLE 8 
Anopheles larvae are treated with dexamethasone or 
dexamethasone and eSculletin and/or the Bacillus thurigien 
Sis Serotype H-14. For field application against floodwater 
mosquitos, 500 grams of Bacillus thurigiensis wettable 
powder is suspended in 10 liters of phosphate buffered saline 
or phosphate buffered Saline with 1 mg/ml dexamethasone 
or phosphate buffered Saline with 1 mg/ml of dexametha 
Sone and eSculletin. The mixture is applied by pressurized 
SprayerS on one ha of water Surface. Some areas are treated 
with 1 mg/ml of dexamethasone in phosphate buffered Saline 
alone or 1 mg/ml dexamethasone and 1 mg/ml esculetin of 
phosphate buffered saline. The effect of inhibitors of 
eicosanoid biosynthesis on mosquito growth is observed in 
the presence and absence of a known bio-control agent 
Bacillus thurigiensis Serotype H-14. An increase in mortality 
associated with the infection of Bacillus thurigiensis in the 
presence of inhibitors of eicosanoid biosynthesis is likely. 
What is claimed is: 
1. A method of altering a cellular immune response of an 
arthropod comprising: administering a pharmaceutical com 
position to an arthropod in an effective amount to inhibit an 
eicosanoid-mediated cellular immune response of the 
arthropod, the composition comprising a biologically active 
agent which is effective to inhibit eicosanoid-mediated cel 
lular immune responses of the arthropod and a physiologi 
cally acceptable carrier. 
2. A method of claim 1, wherein the biologically active 
agent is an eicosanoid biosynthesis inhibitor Selected from 
the group consisting of cinnamic acid, glucocorticoids, 
dihydroxybenzopyran ketones, methanoleukotrienes, 
b in aphthale ne S, naphthale ne acetic acids, 
phosphorylcholines, indole acetic acids, dihydropyridine 
carboxylic acids, phenanthrene carboxylic acids, Salicylic 
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acid, Salicylic acid acetate, neomycins, benzoxazoleacetic 
acids, and dihydroxyanthrones. 
3. A method of claim 1, wherein the biologically active 
agent is Selected from the group consisting of EbSelen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), REV-5901 (2- 
3(1-hydroxy hexyl)phenoxy methylquinoline 
hydrochloride), REV-5901 paraisomer, cinnamyl-3,4- 
dihydroxyl-a-cyano-cinnamate (CDC), Baicalein (5,6,7- 
trihydroxyflavone), caffeic acid, curcumin, CDP-choline, 
5,6-dehydro-arachidonic acid, dexamethasone, DEDA (7,7- 
dimethyl-eicosadienoic acid), dipyridamole, ETYA (5,8,11, 
14-eicosatetraynoic acid), ETI (5,8,11-eicosatriynoic acid), 
eSculletin, gossypol, indomethacin, 5,6-methanoleukotriene 
A methyl ester, naproxen, NDGA (nordihydroguaiaretic 
acid), oleyloxyethyl phosphorylcholine, phenidone, chlor 
promazine HCl, manoalide, nifedipine, aminocephalospo 
ranic acid, aristolochic acid, Compound 48/80, neomycin 
Sulfate, aspirin, benoxaprofen, AA-861 (2-(12-hydroxy-5, 
10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone), 
nafazatrom, quericetrin, REV-5367, REV-5741, REV-5747, 
REV-5827, REV-5875, REV-5965, REV-6080, anthralin, 
cyclooxygenase inhibitors, 5-lipoxygenase inhibitors, 
12-lipoxygenase inhibitors, and phospholipase inhibitors. 
4. A method of claim 1, wherein the biologically active 
agent is Selected from the group consisting of 13-APA (13-azaprostanoic acid), carbacyclin, CTA (carbocyclic 
thromboxane A2), U-44069 (9,11-dideoxy-11-C-9-C.- 
epoxymethanoprostaglandin F2O), U-46619 ((15S)-15 
hydroxy-11-C-9-O-(epoxymethano)prosta-5(Z), 13(E)- 
dienoic acid), DSCG (cromolyn), Oxatomide, PTA, (pinane 
thromboxane A2), and Xanthines. 
5. A method according to claim 1, wherein the composi 
tion further comprises a Surface active agent. 
6. A method according to claim 1, wherein administering 
the composition comprises Spraying the composition onto 
the arthropod. 
7. A method according to claim 1, wherein administering 
the composition comprises injecting the composition into 
the arthropod. 
8. A method according to claim 1, wherein administering 
the composition comprises feeding the composition to the 
arthropod. 
9. A method of decreasing cellular immunity of an arthro 
pod to disease, comprising administering to the arthropod a 
biopesticide composition in an effective amount to decrease 
a cellular immune response, the composition comprising a 
biologically active agent which inhibits eicosanoid 
mediated cellular immune responses and a physiologically 
acceptable carrier. 
10. A method of claim 9, wherein the biologically active 
agent is Selected from the group consisting of cinnamic 
acid, glucocorticoids, dihydroxybenzopyran ketones, 
methanoleukotrienes, binaphthalenes, naphthalene acetic 
acids, phosphorylcholines, indole acetic acids, dihydropyri 
dine carboxylic acids, phenanthrene carboxylic acids, Sali 
cylic acid, Salicylic acid acetate, neomycins, benzox 
aZOleacetic acids, and dihydroxyanthrones. 
11. A method of claim 9, wherein the biologically active 
agent is Selected from the group consisting of EbSelen 
(2-phenyl-1,2-benzisoselenazol-3(2H)-one), REV-5901 (2- 
3(1-hydroxy hexyl)phenoxy methylquinoline 
hydrochloride), REV-5901 paraisomer, cinnamyl-3,4- 
dihydroxyl-a-cyano-cinnamate (CDC), Baicalein (5,6,7- 
trihydroxyflavone), caffeic acid, curcumin, CDP-choline, 
5,6-dehydro-arachidonic acid, dexamethasone, DEDA (7,7- 
dimethyl-eicosadienoic acid), dipyridamole, ETYA (5,8,11, 
14-eicosatetraynoic acid), ETI (5,8,11-eicosatriynoic acid), 
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eSculletin, gossypol, indomethacin, 5,6-methanoleukotriene 
A methyl ester, naproxen, NDGA (nordihydroguaiaretic 
acid), oleyloxyethyl phosphorylcholine, phenidone, chlor 
promazine HCl, manoalide, nifedipine, aminocephalospo 
ranic acid, aristolochic acid, Compound 48/80, neomycin 
Sulfate, aspirin, benoxaprofen, AA-861 (2-(12-hydroxy-5, 
10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone), 
nafazatrom, quericetrin, REV-5367, REV-5741, REV-5747, 
REV-5827, REV-5875, REV-5965, REV-6080, anthralin, 
cyclooxygenase inhibitors, 5-lipoxygenase inhibitors, 
12-lipoxygenase inhibitors, and phospholipase inhibitors. 
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12. A method of claim 9, wherein the biologically active 
agent is Selected from the group consisting of 13-APA 
(13-azaprostanoic acid), carbacyclin, CTA (carbocyclic 
thromboxane A2), U-44069 (9,11-dideoxy-11-C-9-C.- 
epoxymethanoprostaglandin F2O), U-46619 ((15S)-15 
hydroxy-11-C-9-O-(epoxymethano)prosta-5(Z), 13(E)- 
dienoic acid), DSCG (cromolyn), Oxatomide, PTA, (pinane 
thromboxane A2), and Xanthines. 
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